These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21870660)

  • 1. Natural toxin implicated as triggering Parkinson's disease.
    Pak J Biol Sci; 2011 Feb; 14(3):255. PubMed ID: 21870660
    [No Abstract]   [Full Text] [Related]  

  • 2. [Reactive oxygen species and 3,4-dihydroxyphenylacetaldehyde in pathogenesis of Parkinson disease].
    Rybakowska I; Szreder G; Kaletha K; Barwina M; Waldman W; Sein Anand J
    Przegl Lek; 2011; 68(8):486-7. PubMed ID: 22010445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.
    Rojo AI; Montero C; Salazar M; Close RM; Fernández-Ruiz J; Sánchez-González MA; de Sagarra MR; Jackson-Lewis V; Cavada C; Cuadrado A
    Eur J Neurosci; 2006 Oct; 24(7):1874-84. PubMed ID: 17067291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
    Landau AM; Kouassi E; Siegrist-Johnstone R; Desbarats J
    Mov Disord; 2007 Feb; 22(3):403-7. PubMed ID: 17230468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechols in post-mortem brain of patients with Parkinson disease.
    Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Basile MJ; Mash DC
    Eur J Neurol; 2011 May; 18(5):703-10. PubMed ID: 21073636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
    Zbarsky V; Datla KP; Parkar S; Rai DK; Aruoma OI; Dexter DT
    Free Radic Res; 2005 Oct; 39(10):1119-25. PubMed ID: 16298737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The aetiology of idiopathic Parkinson's disease.
    Ramsden DB; Parsons RB; Ho SL; Waring RH
    Mol Pathol; 2001 Dec; 54(6):369-80. PubMed ID: 11724911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological models of Parkinson's disease in rodents.
    Klivenyi P; Vecsei L
    Methods Mol Biol; 2011; 793():211-27. PubMed ID: 21913103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased dopamine in the retinas of patients with Parkinson's disease.
    Harnois C; Di Paolo T
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2473-5. PubMed ID: 2243012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous regeneration in Parkinson's disease: do we need orthotopic dopaminergic neurogenesis?
    Hermann A; Storch A
    Stem Cells; 2008 Nov; 26(11):2749-52. PubMed ID: 18719222
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.
    Lotharius J; Brundin P
    Nat Rev Neurosci; 2002 Dec; 3(12):932-42. PubMed ID: 12461550
    [No Abstract]   [Full Text] [Related]  

  • 14. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease.
    Xie HR; Hu LS; Li GY
    Chin Med J (Engl); 2010 Apr; 123(8):1086-92. PubMed ID: 20497720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.
    Li SW; Lin TS; Minteer S; Burke WJ
    Brain Res Mol Brain Res; 2001 Sep; 93(1):1-7. PubMed ID: 11532332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures.
    Kress GJ; Reynolds IJ
    Neurobiol Dis; 2005 Dec; 20(3):639-45. PubMed ID: 15996475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neurotoxin candidates as pathogenic agents of Parkinson's disease].
    Naoi M
    No To Shinkei; 1997 Sep; 49(9):793-803. PubMed ID: 9310995
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease.
    Uhl GR
    Ann Neurol; 1998 May; 43(5):555-60. PubMed ID: 9585349
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.